Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$1.48MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Shawn K. Singh
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 41
- Beta
- 0.39
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -23.98
Financials
Revenue
$1.48M+18.1%Net Income
$-13.03MEBITDA
$-12.83MFree Cash Flow
$-14.71MEPS (diluted)
$-0.30Shares Outstanding (diluted)
42.98M+15934.1%Operating Expenses
$14.82MCash & Debt
$31.73MReturn of Capital
$0.00Revenue by Segment (annual)
$1.11MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.27M | $-69.69M | $-1.83 |
| 2025 | $486.0K | $-51.42M | $-1.67 |
| 2024 | $1.06M | $-29.36M | $-1.52 |
| 2023 | $-227.0K | $-59.25M | $-8.51 |
| 2022 | $1.11M | $-47.76M | $-7.38 |
| 2021 | $1.09M | $-17.93M | $-14.74 |
| 2020 | $0.00 | $-20.77M | $-14.21 |
| 2019 | $0.00 | $-24.59M | $-25.83 |
| 2018 | $0.00 | $-14.35M | $-30.98 |
| 2017 | $1.25M | $-10.26M | $-40.85 |
| 2016 | $0.00 | $-47.22M | $-801.28 |
| 2015 | $0.00 | $-13.89M | $-318.27 |
| 2014 | $0.00 | $-2.97M | $-81.00 |
| 2013 | $200.4K | $-12.89M | $-426.99 |
Valuation
VTGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
123+22.50%Social Signal Score
Mentions (5)
- Newsschaeffersresearch.com·10d ago·Positive
2 Falling Stocks Call Traders Are Targeting Today Options traders are buying the dip in two stocks this morning, with Meta Platforms (NASDAQ:META) and Vistagen Therapeutics (NASDAQ:VTGN) drawing bullish options activity as both equities trade lower.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
…ull poster presentation can be found on “Publications” section of Company's website SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented positive exploratory data at Psych Congress 2026 in New Orleans.
View source ↗ - Newsglobenewswire.com·14d ago·Positive
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Vistagen to Present at Psych Congress 2026 Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.37 per share
Typical surprise +11.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.30 vs $-0.36beat
- Mon, Jun 15$-0.37 vs $-0.42beat
- Thu, Feb 12$-0.45 vs $-0.51beat
- Thu, Nov 13$-0.54 vs $-0.51miss
- Thu, Aug 7$-0.47 vs $-0.47beat
- Tue, Jun 17$-0.43 vs $-0.52beat
Estimates and results for VTGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VTGN officers and directors.
- Bought
- $18.1m
- Sold
- $107k
4 trades
2 trades
- Commodore Capital Lpbought
- Gin Jerry Bbought
- Adler Reid G.bought
- Singh Shawnbought
- Shah Nimish Psold
- Venrock Healthcare Capital Partners Ii, L.p.sold
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VTGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.